相似文献
1
COVID-19 in bone marrow transplant recipients: reflecting on a single centre experience.
Br J Haematol. 2020 Jul;190(2):e67-e70. doi: 10.1111/bjh.16856. Epub 2020 Jun 23.
2
Pharmacist-driven education for solid organ transplant recipients in the COVID-19 era.
Clin Transplant. 2020 Aug;34(8):e14013. doi: 10.1111/ctr.14013. Epub 2020 Jul 6.
3
Covid-19 and Kidney Transplantation.
N Engl J Med. 2020 Jun 18;382(25):2475-2477. doi: 10.1056/NEJMc2011117. Epub 2020 Apr 24.
4
COVID-19 and liver transplantation.
Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):526-528. doi: 10.1038/s41575-020-0347-z.
5
Novel Coronavirus-19 (COVID-19) in the immunocompromised transplant recipient: #Flatteningthecurve.
Am J Transplant. 2020 Jul;20(7):1765-1767. doi: 10.1111/ajt.15890. Epub 2020 Apr 12.
6
A kidney transplant recipient with nausea, vomiting, and diarrhea after a recent COVID-19 exposure.
Am J Transplant. 2020 Sep;20(9):2618-2620. doi: 10.1111/ajt.16184.
7
Novel coronavirus 2019 pneumonia in a kidney transplant recipient.
Am J Transplant. 2020 Sep;20(9):2599-2601. doi: 10.1111/ajt.15999. Epub 2020 Jun 12.
8
COVID-19 in kidney transplant recipients.
Am J Transplant. 2020 Jul;20(7):1941-1943. doi: 10.1111/ajt.15891. Epub 2020 Apr 12.
9
Immunosuppressive therapy maintenance in a kidney transplant recipient with SARS-CoV-2 pneumonia: A case report.
Am J Transplant. 2020 Jul;20(7):1922-1924. doi: 10.1111/ajt.15920. Epub 2020 May 8.
10
Haemophagocytosis in bone marrow aspirates in patients with COVID-19.
Br J Haematol. 2020 Jul;190(2):e70-e73. doi: 10.1111/bjh.16860. Epub 2020 Jun 12.
引用本文的文献
1
Identifying risk factors for severe omicron infection in allogeneic hematopoietic stem cell transplant recipients with hematologic malignancies.
Cancer Rep (Hoboken). 2024 Jun;7(6):e2103. doi: 10.1002/cnr2.2103.
2
Characteristics and Outcomes of Stem Cell Transplant Patients during the COVID-19 Era: A Systematic Review and Meta-Analysis.
Healthcare (Basel). 2024 Feb 23;12(5):530. doi: 10.3390/healthcare12050530.
3
Outcomes and Management of the SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy.
Transplant Cell Ther. 2024 Jan;30(1):116.e1-116.e12. doi: 10.1016/j.jtct.2023.09.027. Epub 2023 Oct 6.
4
Prolonged SARS-CoV-2 infection during autologous hematopoietic stem cell transplantation from Hodgkin's lymphoma: a case report.
Pan Afr Med J. 2023 Mar 16;44:133. doi: 10.11604/pamj.2023.44.133.36277. eCollection 2023.
5
Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry.
Front Immunol. 2023 Mar 7;14:1125824. doi: 10.3389/fimmu.2023.1125824. eCollection 2023.
6
Clinical efficacy analysis of mesenchymal stem cell therapy in patients with COVID-19: A systematic review.
World J Clin Cases. 2022 Sep 26;10(27):9714-9726. doi: 10.12998/wjcc.v10.i27.9714.
7
The Cause-Effect Dilemma of Hematologic Changes in COVID-19: One Year after the Start of the Pandemic.
Hematol Rep. 2022 Mar 28;14(2):95-102. doi: 10.3390/hematolrep14020014.
8
A Portrait of SARS-CoV-2 Infection in Patients Undergoing Hematopoietic Cell Transplantation: A Systematic Review of the Literature.
Curr Oncol. 2022 Jan 13;29(1):337-349. doi: 10.3390/curroncol29010030.
9
Pulmonary aspergillosis and cryptococcosis as a complication of COVID-19.
Med Mycol Case Rep. 2022 Mar;35:22-25. doi: 10.1016/j.mmcr.2022.01.003. Epub 2022 Jan 6.
10
COVID-19 in the context of autologous hematopoietic stem cell transplantation for a patient with autoimmune disease.
Curr Res Transl Med. 2022 May;70(2):103332. doi: 10.1016/j.retram.2021.103332. Epub 2021 Dec 24.
本文引用的文献
1
COVID-19 outcomes in patients with hematologic disease.
Bone Marrow Transplant. 2020 Nov;55(11):2180-2184. doi: 10.1038/s41409-020-0931-4. Epub 2020 May 6.
2
The trinity of COVID-19: immunity, inflammation and intervention.
Nat Rev Immunol. 2020 Jun;20(6):363-374. doi: 10.1038/s41577-020-0311-8. Epub 2020 Apr 28.
3
COVID-19 in persons with haematological cancers.
Leukemia. 2020 Jun;34(6):1637-1645. doi: 10.1038/s41375-020-0836-7. Epub 2020 Apr 24.
4
Asymptomatic Transmission, the Achilles' Heel of Current Strategies to Control Covid-19.
N Engl J Med. 2020 May 28;382(22):2158-2160. doi: 10.1056/NEJMe2009758. Epub 2020 Apr 24.
5
Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality.
Int J Antimicrob Agents. 2020 May;55(5):105954. doi: 10.1016/j.ijantimicag.2020.105954. Epub 2020 Mar 29.
6
Clinical Characteristics of Coronavirus Disease 2019 in China.
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
7
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.
Lancet Oncol. 2020 Mar;21(3):335-337. doi: 10.1016/S1470-2045(20)30096-6. Epub 2020 Feb 14.
8
IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes.
J Clin Invest. 2019 Jul 29;129(9):3625-3639. doi: 10.1172/JCI126363.
9
Multidimensional assessment of alveolar T cells in critically ill patients.
JCI Insight. 2018 Sep 6;3(17). doi: 10.1172/jci.insight.123287.
10
Suppression of human B lymphocyte function by cyclophosphamide.
J Immunol. 1982 Jun;128(6):2453-7.
Zotero 插件